El-Gendi Saba, Abdelzaher Eman, Mostafa Mohamed Farouk, Sheasha Ghada Abu
Department of Pathology, Faculty of Medicine, University of Alexandria, 29 Fawzy Moaaz Street, Smouha, 21646, Alexandria, Egypt.
Department of Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
Tumour Biol. 2016 Mar;37(3):3173-83. doi: 10.1007/s13277-015-4129-0. Epub 2015 Oct 2.
Fibroblast growth factor 18 (FGF18) has been suggested to play important roles in promoting progression of ovarian high-grade serous carcinoma. Our aim was to investigate FGF18 expression in the whole spectrum of serous and mucinous ovarian tumors, highlighting differences in expression within the adenoma-carcinoma sequence and differences between type I and type II tumors. We also aimed to test the prognostic significance of this expression and its relation to microvessel density (MVD). We evaluated the immunohistochemical expression of FGF18 and CD31 in 103 ovarian tumors and statistically analyzed their association with clinicopathological variables and patients' outcome. FGF18 score increased significantly within the adenoma-carcinoma sequence for serous and mucinous tumors. MVD increased significantly only among serous tumors. FGF18 and MVD correlated significantly (overall and among serous tumors only) and were significantly higher in type II than type I tumors. Cox regression models were built. Independent predictors could not be determined due to multicollinearity between the predictors. However, the combination of International Federation of Gynecology and Obstetrics (FIGO) stage, ovarian carcinoma type, and/or FGF18 score achieved the highest predictability of poor prognosis. FGF18 could play a role within the adenoma-carcinoma sequence in type I tumors and might modulate angiogenesis among serous tumors. Our findings further augment the differences between type I and type II tumors. The combination of FIGO stage, ovarian carcinoma type, and/or FGF18 score could predict poor prognosis among ovarian carcinoma patients. Our work identifies FGF18 in ovarian neoplasia as a promising field of research, although evaluation of the performance of the developed models is still needed.
成纤维细胞生长因子18（FGF18）被认为在促进卵巢高级别浆液性癌进展中发挥重要作用。我们的目的是研究FGF18在浆液性和黏液性卵巢肿瘤全谱中的表达情况，突出腺瘤-癌序列内的表达差异以及I型和II型肿瘤之间的差异。我们还旨在测试这种表达的预后意义及其与微血管密度（MVD）的关系。我们评估了103例卵巢肿瘤中FGF18和CD31的免疫组化表达，并对它们与临床病理变量及患者预后的相关性进行了统计学分析。浆液性和黏液性肿瘤的腺瘤-癌序列中FGF18评分显著增加。仅浆液性肿瘤中的MVD显著增加。FGF18与MVD显著相关（总体及仅在浆液性肿瘤中），且II型肿瘤中的FGF18和MVD显著高于I型肿瘤。构建了Cox回归模型。由于预测因素之间存在多重共线性，无法确定独立预测因素。然而，国际妇产科联合会（FIGO）分期、卵巢癌类型和/或FGF18评分的组合对不良预后具有最高的预测性。FGF18可能在I型肿瘤的腺瘤-癌序列中发挥作用，并可能调节浆液性肿瘤中的血管生成。我们的研究结果进一步强化了I型和II型肿瘤之间的差异。FIGO分期、卵巢癌类型和/或FGF18评分的组合可预测卵巢癌患者的不良预后。我们的工作确定卵巢肿瘤中的FGF18是一个有前景的研究领域，尽管仍需要评估所建立模型的性能。
